



Pergamon

Geraniol-Derived 1,2,4-Trioxanes with Potent In-Vivo Antimalarial Activity[☆]

Chandan Singh,^{a,*} Nitin Gupta^a and Sunil K. Puri^b^aDivision of Medicinal Chemistry, Central Drug Research Institute, Lucknow 226001, India^bDivision of Parasitology, Central Drug Research Institute, Lucknow 226001, India



Received 25 April 2003; accepted 15 July 2003

Abstract—Geraniol, an abundantly available naturally occurring allylic alcohol, has been used as a starting material to prepare a series of 6-[α -(3'-aryl-3'-hydroxypropyl)vinyl]-1,2,4-trioxanes. Some of these novel trioxanes have shown very promising anti-malarial activity against multi-drug resistant *Plasmodium yoelii* in mice by both intramuscular (im) and oral routes.

© 2003 Elsevier Ltd. All rights reserved.

Artemisinin **1**, the antimalarial principle of Chinese traditional drug *Artemisia annua* and its derivatives are highly potent antimalarials, active against multi-drug resistant malaria.¹ The fact that these compounds owe their antimalarial activity to peroxide group, present in the form of a 1,2,4-trioxane in their molecular structures, has led to the current interest in synthetic 1,2,4-trioxanes.²

In continuation with our studies in this area,^{2g,3} we have recently reported the synthesis and antimalarial activity of a series of geraniol-based 1,2,4-trioxanes.⁴ Trioxane **3**, the best compound in this series showed only moderate activity against multi-drug resistant *Plasmodium yoelii* in mice. The methodology for preparation of these trioxanes also suffered from two serious limitations; (i) photooxygenation of geraniol **2**, the key step in the synthesis, gave a complex mixture of hydroperoxides resulting in very poor yield of the desired compounds, (ii) only limited structural variations were possible. In the present study, we have used aldehyde acetate **4**, easily accessible from geranyl acetate in two steps,⁵ to prepare a series of new hydroxy-functionalized 1,2,4-trioxanes. Several of these trioxanes have shown promising antimalarial activity against multi-drug resistant *P. yoelii* in mice by both oral and intramuscular (im) routes.



Scheme 1. Reaction conditions: (a) (i) ArMgBr, dry Et₂O, 0°C to rt, 3 h; (ii) H₂O, 0°C; (b) hv, O₂, methylene blue, MeCN, 0°C, 4–6 h; (c) ketone, TsOH, CH₂Cl₂, rt, 1 h.

[☆]CDRI Communication no.: 6401.

*Corresponding author. Tel.: +91-522-222-4273; fax: +91-522-222-3405; e-mail: chandancdri@yahoo.com

Table 1. In vivo antimalarial activity of trioxanes against *P. yoelii* in Swiss mice


Compd	Dose (mg/kg/day)	Route	% Suppression on day 4 ^a	Mice alive on day 28	Mean survival time ^b (MST)±SE
3	96	im	100.0	2/5	19.57±2.14
	48		100.0	0/5	14.80±2.23
	24		67.7	0/5	12.20±2.24
7a	96	im	100.0	0/5	14.80±1.06
	48	im	97.0	0/5	12.60±1.12
	96	oral	30.0	0/5	08.20±0.53
7b	96	im	100.0	2/5	14.57±0.83
	48		98.4	0/5	14.75±0.75
	96		29.6	0/5	07.40±0.51
7c	96	im	100.0	1/5	14.75±1.48
	48		93.4	0/5	15.75±2.37
	96		81.3	0/5	10.40±0.93
7d	96	im	100.0	2/5	17.33±1.75
	48		100.0	0/5	16.75±1.23
	24		85.2	0/5	11.80±1.53
	96		100.0	0/5	16.00±1.22
	48		94.3	0/5	12.00±1.14
8a	96	im	94.5	0/5	14.40±1.21
	48		90.5	0/5	12.60±1.21
	96		65.0	0/5	11.60±1.12
8b	96	im	100.0	5/5	> 28
	48		97.1	0/5	16.00±1.93
	96		88.8	0/5	10.20±0.53
8c	96	im	100.0	4/5	16.00±0.00
	48		93.4	0/5	14.20±1.33
	96		68.4	0/5	13.00±1.67
8d	96	im	96.4	4/5	14.00±0.00
	48		81.0	0/5	10.60±0.68
	96		100.0	0/5	13.80±0.53
	48		77.5	0/5	11.20±1.36
9a	96	im	100.0	5/5	> 28
	48		98.1	2/5	15.57±0.33
	96		100.0	2/5	16.57±1.21
	48		62.4	0/5	09.00±0.71
9b	96	im	100.0	5/5	> 28
	48		78.9	0/5	15.00±0.95
	96		100.0	5/5	> 28
	48		90.8	0/5	10.20±0.85
9c	96	im	72.13	2/5	15.33±2.31
	96		100.0	3/5	17.00±3.00
	48		100.0	2/5	15.57±1.75
	24		87.1	0/5	10.40±1.24
9d	96	im	79.0	3/5	14.50±0.50
	96		100.0	2/5	17.33±1.45
	48		100.0	2/5	17.57±2.02
	24		90.4	0/5	08.80±0.53
Artemisinin	48	im	100.0	5/5	> 28
	24		100.0	4/5	16.00±0.00
Chloroquine	96	oral	100.0	4/5	20.00±0.00
	48		100.0	2/5	17.60±1.33
Vehicle control	—	—	—	0/15	07.00±0.14

^aPercent suppression = [(C–T)/C]×100; where C = parasitaemia in control group, and T = parasitaemia in treated group.

^bMST calculated for the mice which died during 28-day observation period.

Chemistry

Geranyl acetate was converted to aldehyde acetate **4** using a known procedure.⁵ Reaction of **4** with excess of Grignard reagents prepared from bromobenzene, 4-bromochlorobenzene, 1-bromonaphthalene and 4-bromobiphenyl furnished allylic alcohols **5a–d** in 60–75% yields. Methylene blue sensitized photooxygenation of allylic alcohols **5a–d** in MeCN furnished β -hydroxyhydroperoxides **6a–d** in 30–45% yield, as inseparable mixture of diastereomers. Acid catalyzed condensation of β -hydroxyhydroperoxides **6a–d** with cyclopentanone, cyclohexanone, and 2-adamantanone furnished hydroxy-functionalized 1,2,4-trioxanes **7a–d**, **8a–d**, **9a–d** in 50–74% yields (Scheme-1), again as inseparable mixture of diastereomers. In most of the cases these diastereomers were indistinguishable even by ¹H NMR, and only ¹³C NMR could differentiate them (Scheme 1).⁶



Antimalarial Activity

Trioxanes **7a–d**, **8a–d**, and **9a–d** were initially screened for their antimalarial activity against multi-drug resistant *P. yoelii* in Swiss mice⁷ at a highest dose of 96 mg/kg⁸ by both intramuscular (im) and oral routes. The trioxanes showing activity at 96 mg/kg by either routes were further evaluated at 48 and 24 mg/kg. The results are shown in Table 1.

Results and discussion

Trioxane **9b** is the best compound in the series. It shows 100% clearance of parasitaemia on day 4 at 96 mg/kg by both im and oral routes and all the animals survive beyond day 28. Trioxane **9a** is the next best compound in the series. At 96 mg/kg given im, this compound shows complete clearance of parasitaemia on day 4 and all the animals survive beyond day 28. Even at 48 mg/kg, this compound shows almost complete clearance of parasitaemia on day 4 and 40% of the animals survive beyond day 28. This trioxane also shows complete clearance of parasitaemia on day 4 at 96 mg/kg by oral route and 40% of the animals survive beyond day 28.

Both these trioxanes are derived from 2-adamantanone. The other two trioxanes derived from 2-adamantanone (**9c** and **9d**) also show significant activities. **9c** provides 60% protection at 96 mg/kg and 40% protection at 48 mg/kg when given orally. Similarly trioxane **9d** provides 40% protection when given im at 96 and 48 mg/kg. Both these trioxanes show complete clearance of parasitaemia on day 4 when given orally at 96 and 48 mg/kg. Trioxanes **8b** and **8c** derived from cyclohexanone also show complete clearance of parasitaemia on day 4 at 96 mg/kg given im and provide 100 and 80% protection, respectively. Trioxane **8d** though shows only 96% clearance of parasitaemia on day 4 but provides 80% protection when given im. Trioxanes **7b**, **7c**, and **7d** derived from cyclopentanone also show complete clearance of parasitaemia on day 4 at 96 mg/kg given by im route and provide 40, 20 and 40% protection, respectively. Trioxanes **7c** and **7d** also show significant suppression of parasitaemia on day 4 when given orally but none of the treated mice survives beyond day 28. Similarly, trioxanes **7a** and **8a** show significant suppression of parasitaemia on day 4 at 96 and 48 mg/kg given im, but none of the treated animals survive, beyond day 28. Trioxane **3**, the best compound of the earlier series, shows 100% clearance of parasitaemia at 96 and 48 mg/kg on day 4 when given im but provides only 40% protection at 96 mg/kg (Table 1).

A high order of activity shown by trioxanes having adamantane moiety (**9a–d**) is in agreement with our earlier observations.³ In this series, the introduction of very hydrophobic aryl groups such as naphthyl and biphenyl (**9c** and **9d**) leads to decrease in the activity. For trioxanes with adamantane moiety a phenyl/chlorophenyl in the side chain provides the desired level of hydrophobicity to these molecules. Introduction of naphthyl and biphenyl groups in the side chain of the trioxanes derived from cyclohexanone (**8c** and **8d**) has favorable effect on the activity.

Conclusion

Using geraniol derived trioxane **3** as lead, we have prepared a new series of hydroxy-functionalized 1,2,4-trioxanes, several of which have shown very promising activity against multi-drug resistant *P. yoelii* in mice both by oral and im routes.

Acknowledgements

Nitin Gupta is grateful to the Council of Scientific and Industrial Research (CSIR), New Delhi for award of Senior Research Fellowship.

References and Notes

- (a) Klayman, D. L. *Science* **1985**, 228, 1049. (b) Luo, X. D.; Shen, C. C. *Med. Res. Rev.* **1987**, 7, 29. (c) Zaman, S. S.; Sharma, R. P. *Heterocycles* **1991**, 32, 1593. (d) Cumming, J. N.; Ploypradith, P.; Posner, G. H. *Adv. Pharmacol.* **1997**,

- 37, 253. (e) Zhou, W. S.; Xu, X. X. *Acc. Chem. Res.* **1994**, *27*, 211. (f) Bhattacharya, A. K.; Sharma, R. P. *Heterocycles* **1999**, *51*, 1681.
2. (a) O'Neill, P. M.; Pugh, M.; Davies, J.; Ward, S. A.; Park, B. K. *Tetrahedron Lett.* **2001**, *42*, 4569. (b) Bloodworth, A. J.; Johnson, K. A. *Tetrahedron Lett.* **1994**, *35*, 8057. (c) Bloodworth, A. J.; Curtis, R. J.; Spencer, M. D.; Tallant, M. S. *Tetrahedron* **1993**, *49*, 2729. (d) Posner, G. H.; Oh, C. H.; Tilhous, W. K. *Tetrahedron Lett.* **1991**, *34*, 4235. (e) Bunelle, W. H.; Isbell, T. A.; Bames, C. L.; Qualls, S. *J. Am. Chem. Soc.* **1991**, *113*, 8168. (f) Avery, M. A.; Jennings-White, C.; Chong, W. K. M. *J. Org. Chem.* **1989**, *54*, 1792. (g) Singh, C. *Tetrahedron Lett.* **1990**, *33*, 6901. (h) Kepler, J. A.; Philip, A.; Lee, Y. W.; Morey, M. C.; Carroll, F. I. *J. Med. Chem.* **1988**, *31*, 713. (i) Jefford, C. W.; Jaggi, D.; Boukouvalas, J.; Burger, S. *J. Am. Chem. Soc.* **1983**, *105*, 6497.
3. (a) Singh, C.; Misra, D.; Saxena, G.; Chandra, S. *Bioorg. Med. Chem. Lett.* **1992**, *2*, 497. (b) Singh, C.; Misra, D.; Saxena, G.; Chandra, S. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 1913.
4. Singh, C.; Gupta, N.; Puri, S. K. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 1913.
5. Dodd, D. S.; Oehlschlager, A. C.; Georgopapadaku, N. H.; Polok, A.-M.; Hartman, P. G. *J. Org. Chem.* **1992**, *57*, 7226.
6. Selected data: Trioxane **7b** (mixture of diastereomers): FT-IR (neat, cm^{-1}) 1597.4, 1646.8, 3435.1; ^1H NMR (200 MHz, CDCl_3) δ 1.70–1.92 (m, 9H), 2.06–2.16 (m, 2H), 2.38–2.44 (m, 1H), 3.78–3.82 (m, 2H), 4.64–4.76 (m, 2H), 5.05 (s, 2H), 7.20–7.40 (m, 4H); ^{13}C NMR (50 MHz, CDCl_3) δ 23.33 (t), 24.70 (t), 29.84 (t), 32.73 (t), 36.97 (t), 37.27 (t), 64.46 (t), 73.04 (d), 73.07 (d), 81.14 (d), 81.22 (d), 114.47 (s), 114.50 (t), 127.23 (2 \times d), 128.67 (2 \times d), 133.31 (s), 142.97 (s), 143.10 (s); FABMS (m/z) 339 and 341 ($\text{M}^+ + 1$). Anal. calcd C 63.81%, H 6.84%; found C 63.58%, H 7.02%. Trioxane **8c** (mixture of diastereomers): FT-IR (neat, cm^{-1}) 1597.5, 1645.4, 3443.8; ^1H NMR (200 MHz, CDCl_3) δ 1.42–1.57 (m, 8H), 1.84–2.31 (m, 6H), 3.68 (dd, 1H, $J=11.8, 3.0$), 3.86–4.01 (m, 1H), 4.69 (dd, 1H, $J=10.2, 3.0$), 5.04 and 5.06 (2 \times s, 2H), 5.45 (m, 1H), 7.45–8.08 (m, 7H); ^{13}C NMR (50 MHz, CDCl_3) δ 22.67 (t), 22.71 (t), 25.94 (t), 29.41 (t), 30.67 (t), 30.72 (t), 35.00 (t), 36.77 (t), 36.82 (t), 62.53 (t), 62.57 (t) 70.80 (d), 70.95 (d), 81.68 (d), 81.75 (d), 102.84 (s), 114.64 (t) 114.87 (t), 123.20 (d), 123.31 (d), 123.49 (d), 125.81 (d), 125.98 (d), 126.48 (d), 126.52 (d), 128.44 (d), 128.48 (d), 129.31 (d), 130.77 (s), 134.28 (s), 140.49 (s) 140.58 (s), 143.94 (s), 144.01 (s); FABMS (m/z) 369 ($\text{M}^+ + 1$). Anal. calcd C 74.97%, H 7.66%; found C 75.20%, H 7.49%. Trioxane **9d** (mixture of diastereomers): FT-IR (neat, cm^{-1}) 1600.8, 1646.5, 3407.3; ^1H NMR (200 MHz, CDCl_3) δ 1.50–2.18 (m, 17H), 2.88 (bs, 1H), 3.72 (dd, 1H, $J=11.8, 3.0$ Hz), 3.94 (dd, 1H, $J=11.8, 10.5$ Hz), 4.70–4.80 (m, 2H), 5.07 (s, 2H), 7.33–7.60 (m, 9H); FABMS (m/z) 447 ($\text{M}^+ + 1$). Anal. calcd: C 78.00%, H 7.67%; found C 77.69%, H 8.01%.
7. The in vivo efficacy of compounds was evaluated against *P. yoelii* (MDR) in Swiss mice model. The colony bred Swiss mice (25 ± 1 g) were inoculated with 1×10^6 parasitised RBC on day zero and treatment was administered to a group of five mice at each dose, from day 0 to 3, in two divided doses daily. The drug dilutions were prepared so as to contain the required amount of the drug (1.2 mg for a dose of 96 mg/kg and 0.6 mg for a dose of 48 mg/kg) in 0.1 mL and administered either intramuscularly or orally for each dose. Parasitaemia level were recorded from thin blood smears between days 4 and 28.⁹ Mice treated with artemisinin and chloroquine served as positive controls.
8. Since artemisinin is active at a dose of 48 mg/kg, we have chosen 96 mg/kg as the highest dose in the primary screening of trioxanes.
9. Puri, S. K.; Singh, N. *Expl. Parasit.* **2000**, *94*, 8.